Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

2017 Complete Response Letters: Fewer Than 2016, Still More Than Years Past

Jan 16 2018

• By Michael Cipriano

Pink Sheet Perspectives 2017 - 2018

Related Content

Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations

Oct 15 2017

Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen

Dec 12 2017

Novel Approvals Were Fewer But Faster At US FDA In 2016

Jan 02 2017

Q&A With US FDA Commissioner Scott Gottlieb

Nov 09 2017

Public Complete Response Letters? Don’t Hold Your Breath

Nov 16 2017

Reader, Be Wary: Sponsors Keep Most 'Complete Response' Letter Content Under Wraps, FDA Says

Jun 29 2015

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down

Nov 08 2016

Related Companies

Viatris Inc.

Biocon, Ltd.

Coherus Oncology, Inc.

Pfizer Inc.

Clovis Oncology, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Complete Response Letters Drug Review Regulation BioPharmaceutical

More from Complete Response Letters

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window